Copertina

Authors' Reply to the Letter on “Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First‐Line Helicobacter pylori Eradication Treatment More Effective? A Three‐Arm, Multicenter Randomized Clinical Trial”

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Zhengchen Yu, Wenjuan Shen, Guochun Lou, Yan Li, Ziming Xie, Jun Ye
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Helicobacter
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Reply: Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First‐Line Helicobacter pylori Eradication Treatment More Effective? A Three‐Arm, Multicenter Randomized Clinical Trial
di: Xinlu Ren, et al.
Pubblicazione: (2025)

Correction to “Long‐Term Effects of Fecal Microbiota Transplantation on Gut Microbiota After Helicobacter pylori Eradication With Bismuth Quadruple Therapy: A Randomized Controlled Trial”
Pubblicazione: (2024)

Vonoprazan Dual or Triple Therapy Versus Bismuth‐Quadruple Therapy as First‐Line Therapy for Helicobacter pylori Infection: A Three‐Arm, Randomized Clinical Trial
di: Ka Shing Cheung, et al.
Pubblicazione: (2024)

Non‐Bismuth Quadruple Concomitant Treatment for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis
di: Pablo Parra, et al.
Pubblicazione: (2026)

Vonoprazan Improves Efficacy of Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter Randomized Controlled Trial
di: Tian‐Lian Yan, et al.
Pubblicazione: (2025)

Optimal Duration of Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis
di: Miao Duan, et al.
Pubblicazione: (2024)

Efficacy and Safety of Vonoprazan‐Based Dual Therapies With Different Antibiotics Versus Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Prospective, Four‐Arm, Randomized Controlled Trial
di: Jie Li, et al.
Pubblicazione: (2026)

Antibiotic Combinations in Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Network Meta‐Analysis
di: Miao Duan, et al.
Pubblicazione: (2025)

Tetracycline Three Times Daily Versus Four Times Daily in Bismuth‐Containing Quadruple Therapy as the First‐Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial
di: Yu‐Ming Ding, et al.
Pubblicazione: (2024)

Letter to the Editor: Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta‐Analysis of Randomized Controlled Trials With Trial Sequential Analysis—Authors' Reply
di: Vivek Mishra, et al.
Pubblicazione: (2025)

Efficacy and Safety of Vonoprazan‐Based Dual, Triple, and Quadruple Therapies for Helicobacter pylori Eradication: A Randomized Controlled Trial
di: Jin‐Yan Zhang, et al.
Pubblicazione: (2026)

Tailored Therapy Guided by Antibiotic Genotypic Resistances and CYP2C19 Polymorphisms Detected From Fecal Specimens for the First‐Line Helicobacter pylori Eradication: A Randomized Controlled Trial
di: Baojun Suo, et al.
Pubblicazione: (2025)

Exosome‐Based Detection of Helicobacter pylori Infection and Clarithromycin Resistance in Children
di: Minghui Song, et al.
Pubblicazione: (2026)

Helicobacter pylori Infection in Children: To Eradicate or Not to Eradicate?
di: Marco Manfredi, et al.
Pubblicazione: (2024)

Efficacy of Bismuth Therapy in Eradicating Helicobacter pylori in Children—Data From the RENIHp Registry
di: Gonzalo Botija, et al.
Pubblicazione: (2024)

Tegoprazan‐Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial
di: Jae Yong Park, et al.
Pubblicazione: (2026)

Efficacy and Safety of Levofloxacin‐ Versus Moxifloxacin‐Based Nitazoxanide Quadruple Therapy as Second‐Line Treatment for Helicobacter pylori in Egypt: A Randomized Multicenter Trial
di: Gasser El‐Azab, et al.
Pubblicazione: (2026)

Efficacy of Bismuth Quadruple Therapy in the Treatment of Helicobacter pylori‐Infected Peptic Ulcer Children in Vietnam
di: Thi Minh Phuong Do, et al.
Pubblicazione: (2024)

Seven‐Day Versus 14‐Day Tegoprazan and Tetracycline‐Containing Quadruple Therapy for First‐Line Eradication of Helicobacter pylori Infection: A Randomized, Open‐Label, Noninferiority Trial
di: Xue‐Ping Nan, et al.
Pubblicazione: (2025)

Correction to “Tegoprazan‐Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial”
Pubblicazione: (2026)

Efficacy and Safety of Keverprazan–Amoxicillin Dual Regimen in Initial Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial
di: Shanshan Wei, et al.
Pubblicazione: (2026)

Efficacy of Three Amoxicillin Doses in Vonoprazan Dual Therapy for Helicobacter pylori Eradication: A Randomized Noninferiority Trial
di: Ruolin Peng, et al.
Pubblicazione: (2025)

Efficacy and Safety of Vonoprazan in Dual/Triple/Quadruple Regimens Both in First‐Line and Rescue Therapy for Helicobacter pylori Eradication: A Systematic Review With Meta‐Analysis
di: Belén Martínez Benito, et al.
Pubblicazione: (2024)

Droplet Digital PCR ‐Based Detection of Clarithromycin Resistance on Rapid Urease Test Samples Predicts Helicobacter pylori Eradication Success: A New Zealand Cohort Study
di: Stephen James Inns, et al.
Pubblicazione: (2025)

Optimization of Minocycline‐Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real‐World Evidence Study
di: Yu Huang, et al.
Pubblicazione: (2024)

Letter to the Editor: “Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta‐Analysis of Randomized Controlled Trials With Trial Sequential Analysis”
di: Ben‐Gang Zhou, et al.
Pubblicazione: (2025)

Comparison of Cefuroxime‐Based Dual Therapy With Quadruple Therapy in Helicobacter pylori‐Infected Treatment‐Naive Patients: A Prospective, Multicenter, Randomized Controlled Trial
di: Ji‐Yan Li, et al.
Pubblicazione: (2025)

Tegoprazan‐Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China
di: Xueyan Lin, et al.
Pubblicazione: (2024)

Second‐ and Third‐Line Therapies for Helicobacter pylori Eradication in Slovenia: Data From 2013–2023 of the European Registry on H. pylori Management
di: Bojan Tepes, et al.
Pubblicazione: (2025)

High‐Dose Dual Therapy Versus Bismuth‐Containing Quadruple Therapy as Rescue Treatment for Helicobacter pylori Infection: Systematic Review and Meta‐Analysis
di: Liang Zhang, et al.
Pubblicazione: (2026)

EUROHELICAN —Accelerating Gastric Cancer Reduction Through Helicobacter pylori Eradication
di: Bojan Tepeš, et al.
Pubblicazione: (2026)

Helicobacter pylori Eradication in Older Individuals: A Systematic Review and Meta‐Analysis
di: Sun Jae Moon, et al.
Pubblicazione: (2025)

Comparison of Therapeutic Outcomes Between Concomitant Therapy and Tailored Therapy for Helicobacter pylori: A Multicenter, Prospective, and Randomized Study
di: Young Sin Cho, et al.
Pubblicazione: (2025)

Cost‐Effectiveness of Population‐Based Helicobacter pylori Screening With Eradication for Optimal Age of Implementation
di: Akiko Kowada
Pubblicazione: (2024)

Interpretation the Results of Eradicating Helicobacter pylori Infection Causing Colorectal Cancer Could Be Cautious
di: Lo‐Yip Yu, et al.
Pubblicazione: (2025)

Efficacy of Tetracycline Three Times Daily was Comparable to That of Four Times Daily for Helicobacter pylori Rescue Treatment: A Multicenter, Noninferiority, Randomized Controlled Trial
di: Zhongxue Han, et al.
Pubblicazione: (2024)

Helicobacter pylori Eradication Primary Care First‐Line Prescriptions: Data From 200,000 Patients in a Real‐World Cohort
di: Encarnación Fernández‐Antón, et al.
Pubblicazione: (2026)

Optimizing Duration and Dosing Frequency of Vonoprazan–Amoxicillin Dual Therapy for Helicobacter pylori: A Multicenter Randomized Trial
di: Lulong Tao, et al.
Pubblicazione: (2025)

Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial
di: Qingzhou Kong, et al.
Pubblicazione: (2024)

Exploration of a Potential Amoxicillin MIC Threshold in Bismuth Quadruple Therapy for H. pylori Infection in Southeastern China
di: Ding Lu, et al.
Pubblicazione: (2026)